Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis. (PubMed, Front Pharmacol) - Sep 25, 2026 - "Mavacamten was associated with expected cardiac safety signals and additional exploratory signals, supporting continued surveillance and careful cardiac monitoring. These hypothesis-generating findings require confirmation in independent data sources."
Adverse events • Journal • P4 data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cataract • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Ophthalmology
|
|
Chi Chen; Juan Wu; Tao Zheng
|